Novavax to present clinical trial results of RSV vaccine

Novavax, a clinical-stage biopharmaceutical company, announced on Tuesday that it will present data from recent preclinical and clinical trials of its respiratory syncytial virus F-protein nanoparticle vaccine candidate at a conference next week.

The Rockville, Md.-based company will present the data in poster sessions at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver. The conference runs September 11 through September 13. Both presentations will take place on Wednesday.

In one poster, the company will describe in detail the immunogenicity and safety of its RSV F nanoparticle vaccine observed as part of a Phase I clinical study of 220 healthy elderly adults. Novavax reported the top-line results of the study in July.

In the second poster, Novavax will present data from a preclinical passive immunization and challenge study that evaluated the protective effects of RSV F nanoparticle, vaccine-induced, palivizumab-like antibodies in cotton rats. A cotton rat model was previously predictive for protection in infant passive immunization studies.

RSV causes severe illness in infants, young children, the elderly and adults with underlying pulmonary or chronic cardiac disease. RSV infection causes between 11,000 and 17,000 deaths annually in the U.S. and approximately 160,000 deaths worldwide each year.

There is no approved RSV prophylactic vaccine currently available.